An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis

Amyloid. 2007 Dec;14(4):261-9. doi: 10.1080/13506120701613984.

Abstract

AL amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. This review outlines an overview of high-dose intravenous melphalan and stem cell transplantation in the treatment of AL amyloidosis. An algorithm of our recommendations for the treatment of AL amyloidosis is also outlined.

Publication types

  • Review

MeSH terms

  • Algorithms
  • Amyloidosis / diagnosis
  • Amyloidosis / drug therapy*
  • Amyloidosis / surgery*
  • Dose-Response Relationship, Drug
  • Humans
  • Melphalan / administration & dosage
  • Melphalan / therapeutic use*
  • Myeloablative Agonists / administration & dosage
  • Myeloablative Agonists / therapeutic use
  • Practice Guidelines as Topic
  • Stem Cell Transplantation / methods*

Substances

  • Myeloablative Agonists
  • Melphalan